Table 1 Baseline characteristics of the study population, Tehran Lipid and Glucose Study (1999–2018)
|  | Men (n = 2446) | Women (n = 2903) | P value |
|---|---|---|---|
Age, year | 55.2 (10.5) | 52.9 (9.2) |  < 0.001 |
SBP, mmHg | 125.9 (20.8) | 127.6 (21.3) | 0.005 |
DBP, mmHg | 79.4 (11.9) | 80.9 (11.1) |  < 0.001 |
FPG, mmol/L | 5.8 (1.9) | 5.9 (2.4) |  < 0.001 |
BMI, kg/m2 | 26.2 (3.9) | 29.2 (4.6) |  < 0.001 |
TC, mmol/L | 5.4 (1.1) | 6.0 (1.2) |  < 0.001 |
Blood pressure status (%) | Â | Â | Â |
 No hypertension | 834 (34.1) | 812 (28.0) |  < 0.001 |
 Pre-hypertension | 836 (34.2) | 963 (33.2) | |
 Hypertension | 776 (31.7) | 1128 (38.9) | |
Glucose tolerance status (%) | Â | Â | Â |
 No diabetes | 1596 (65.2) | 1839 (63.3) | 0.013 |
 Pre-diabetes | 528 (21.6) | 599 (20.6) | |
 Type 2 diabetes | 322 (13.2) | 465 (16.0) | |
Smoking status (%) |  |  |  < 0.001 |
 Past and never | 1744 (71.3) | 2778 (95.7) |  < 0.001 |
 Current | 702 (28.7) | 125 (4.3) | |
Education level (%) | Â | Â | Â |
 < 6 years | 1040 (42.5) | 1927 (66.4) |  < 0.001 |
 6–12 years | 1051 (43.0) | 857 (29.5) | |
 > 12 years | 355 (14.5) | 119 (4.1) | |
Drug use (%) | Â | Â | Â |
 Antihypertensive drugs | 216 (8.8) | 515 (17.7) |  < 0.001 |
 Lipid lowering drugs | 80 (3.3) | 220 (7.6) |  < 0.001 |
 Anti-diabetes drugs | 146 (6.0) | 263 (9.1) |  < 0.001 |
Family history of CVD (%) | 339 (13.9) | 558 (19.2) |  < 0.001 |
History of CHD (%) | 210 (8.6) | 175 (6.0) |  < 0.001 |